Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) Short Interest Update

Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) was the recipient of a significant decrease in short interest in the month of November. As of November 30th, there was short interest totalling 49,500 shares, a decrease of 71.7% from the November 15th total of 175,000 shares. Based on an average daily trading volume, of 172,900 shares, the days-to-cover ratio is currently 0.3 days. Currently, 0.8% of the company’s shares are short sold.

Wall Street Analysts Forecast Growth

Several research analysts recently weighed in on ADIL shares. Rodman & Renshaw began coverage on shares of Adial Pharmaceuticals in a research note on Thursday, November 14th. They set a “buy” rating and a $8.00 price objective on the stock. RODMAN&RENSHAW upgraded shares of Adial Pharmaceuticals to a “strong-buy” rating in a report on Thursday, November 14th.

Adial Pharmaceuticals Price Performance

NASDAQ ADIL opened at $1.10 on Thursday. The business has a 50 day simple moving average of $1.04 and a 200 day simple moving average of $1.08. Adial Pharmaceuticals has a 52-week low of $0.77 and a 52-week high of $4.17.

Adial Pharmaceuticals Company Profile

Adial Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder.